Akebia Therapeutics

160 articles with Akebia Therapeutics

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on January 31, 2019

  2/4/2019

  Akebia Therapeutics, Inc. granted 11 newly-hired employees options to purchase an aggregate of 41,900 shares of Akebia’s common stock on January 31, 2019, as inducements material to each such employee’s entering into employment with Akebia.

• Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Akebia Therapeutics, Inc. today announced that its President and Chief Executive Officer, John P. Butler, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:30 a.m. Pacific Time at the Westin St. Francis in San Francisco.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on December 31, 2018

  1/2/2019

  Akebia Therapeutics, Inc. granted six newly-hired employees options to purchase an aggregate of 45,150 shares of Akebia’s common stock on December 31, 2018, as inducements material to each such employee’s entering into employment with Akebia.

• Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company

  12/13/2018

  Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger.

• Akebia Therapeutics Shareholders Approve Merger with Keryx

  12/11/2018

  Akebia Therapeutics, Inc. today announced that Akebia shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) at a special meeting of Akebia shareholders held earlier today. More than 95% of the shares voted at the special meeting voted in favor of the share issuance proposal.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on November 30, 2018

  12/3/2018

  Akebia Therapeutics, Inc. granted five newly-hired employees options to purchase an aggregate of 49,650 shares of Akebia’s common stock on November 30, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

• Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx

  11/30/2018

  Akebia Therapeutics, Inc. (Nasdaq:AKBA) (“Akebia” or the “Company”) today announced that leading independent proxy advisory firm, Glass Lewis & Co. (“Glass Lewis”), joins Institutional Shareholder Services (“ISS”) in recommending that Akebia shareholders vote “FOR” the shareholder proposals relating to the Company’s proposed merger with Keryx Biopharmaceuticals (Nasdaq:KERX).

• Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx

  11/29/2018

  Akebia Urges Shareholders to Vote “FOR” the Merger-Related Shareholder Proposals Today

• Akebia Therapeutics to Participate in Upcoming November and December 2018 Investor Conferences

  11/20/2018

  Akebia Therapeutics, Inc. today announced that it will participate in the following investor conferences

• Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company

  11/15/2018

  Adrian Adams To Serve as Independent Chairperson of the Board After Merger

• Akebia Therapeutics Sends Letter to Shareholders

  11/13/2018

  Recommends Shareholders Vote “FOR” the Proposals Relating to the Merger

• Akebia Therapeutics Announces Third Quarter 2018 Financial Results

  11/8/2018

  Akebia Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2018.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on October 31, 2018

  11/2/2018

  Akebia Therapeutics, Inc. granted four newly-hired employees options to purchase an aggregate of 25,400 shares of Akebia’s common stock on October 31, 2018, as inducements material to each such employee’s entering into employment with Akebia.

• Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals

  10/30/2018

  Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that it and Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) filed a definitive joint proxy statement with the U.S. Securities and Exchange Commission (“SEC”)

• Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting

  10/9/2018

  Akebia Therapeutics, Inc. today announced two posters to be presented at the upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting in San Diego, California, from October 23 to 28, 2018.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on September 28, 2018

  10/2/2018

  Akebia Therapeutics, Inc. granted six newly-hired employees options to purchase an aggregate of 32,750 shares of Akebia’s common stock on September 28, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

• Akebia Therapeutics to Participate in Upcoming October 2018 Investor Conferences

  9/25/2018

  Akebia Therapeutics, Inc. today announced that it will participate in the following investor conferences:

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on August 31, 2018

  9/4/2018

  Akebia Therapeutics, Inc. granted a newly-hired employee options to purchase an aggregate of 1,250 shares of Akebia’s common stock on August 31, 2018

• Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors

  8/28/2018

  Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the appointment of Cynthia Smith to its Board of Directors.

• 

  SEC Aims Insider Trading Charges at Former Sangamo Therapeutics Executive

  8/24/2018

  The U.S. Securities and Exchange Commission has leveled charges at a former Sangamo Therapeutics Inc. executive and others for an insider-trading scheme that netted more than $1.5 million in “illegal profits.”